8-KItem 2.02 · Results of OperationsItem 8.01 · Other EventsItem 9.01 · Financial Statements
Revvity reports higher third-quarter earnings and raises 2026 guidance
Filed with the SEC on · Summarized by InvestorsBot
Revvity reported third-quarter 2026 revenue of $729 million, up from $699 million a year earlier, while GAAP EPS from continuing operations rose to $0.56 from $0.41 and adjusted EPS increased to $1.38 from $1.18. On a pro forma basis excluding the China Immunodiagnostics business, revenue was $710 million, organic growth was 7%, and the company raised full-year 2026 guidance to approximately $2.86 billion in revenue and $5.40-$5.45 in adjusted EPS; the China IDX divestiture is expected to close by the end of 2027 and could involve $120 million of consideration.